NLTX Annual EBIT
-$59.10 M
+$1.60 M+2.64%
31 December 2022
Summary:
As of February 5, 2025, NLTX annual earnings before interest & taxes is -$59.10 million, with the most recent change of +$1.60 million (+2.64%) on December 31, 2022. During the last 3 years, it has fallen by -$35.85 million (-154.26%).NLTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly EBIT
-$5.57 M
-$2.50 M-81.64%
30 September 2023
Summary:
As of February 5, 2025, NLTX quarterly earnings before interest & taxes is -$5.57 million, with the most recent change of -$2.50 million (-81.64%) on September 30, 2023. Over the past year, it has increased by +$8.04 million (+59.08%).NLTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX TTM EBIT
-$34.60 M
+$8.04 M+18.85%
30 September 2023
Summary:
As of February 5, 2025, NLTX TTM earnings before interest & taxes is -$34.60 million, with the most recent change of +$8.04 million (+18.85%) on September 30, 2023. Over the past year, it has increased by +$25.42 million (+42.35%).NLTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.6% | +59.1% | +42.4% |
| 3 y3 years | -154.3% | +44.7% | +7.2% |
| 5 y5 years | -17.8% | +63.4% | -48.9% |
NLTX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +684.7% | -307.0% | +3331.5% |
Neoleukin Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$5.57 M(+81.6%) | -$34.60 M(-18.9%) |
| June 2023 | - | -$3.07 M(-73.8%) | -$42.64 M(-23.1%) |
| Mar 2023 | - | -$11.72 M(-17.8%) | -$55.45 M(-6.2%) |
| Dec 2022 | -$59.10 M(-2.6%) | -$14.25 M(+4.7%) | -$59.10 M(-1.5%) |
| Sept 2022 | - | -$13.61 M(-14.3%) | -$60.02 M(-3.0%) |
| June 2022 | - | -$15.87 M(+3.3%) | -$61.86 M(+1.2%) |
| Mar 2022 | - | -$15.37 M(+1.3%) | -$61.12 M(+0.7%) |
| Dec 2021 | -$60.70 M(+46.1%) | -$15.17 M(-1.8%) | -$60.70 M(+4.4%) |
| Sept 2021 | - | -$15.45 M(+2.2%) | -$58.16 M(+10.2%) |
| June 2021 | - | -$15.12 M(+1.2%) | -$52.79 M(+11.3%) |
| Mar 2021 | - | -$14.95 M(+18.3%) | -$47.43 M(+14.1%) |
| Dec 2020 | -$41.55 M(+78.8%) | -$12.64 M(+25.4%) | -$41.55 M(+11.5%) |
| Sept 2020 | - | -$10.08 M(+3.1%) | -$37.27 M(-4.4%) |
| June 2020 | - | -$9.77 M(+7.7%) | -$39.00 M(+31.5%) |
| Mar 2020 | - | -$9.07 M(+8.6%) | -$29.66 M(+27.6%) |
| Dec 2019 | -$23.24 M(-26.4%) | -$8.36 M(-29.2%) | -$23.24 M(+21.4%) |
| Sept 2019 | - | -$11.80 M(+2657.0%) | -$19.14 M(-15.1%) |
| June 2019 | - | -$428.00 K(-83.9%) | -$22.54 M(+16.1%) |
| Mar 2019 | - | -$2.66 M(-37.5%) | -$19.42 M(-38.5%) |
| Dec 2018 | -$31.58 M | -$4.26 M(-72.0%) | -$31.58 M(-26.4%) |
| Sept 2018 | - | -$15.20 M(-664.9%) | -$42.92 M(+7.9%) |
| June 2018 | - | $2.69 M(-118.2%) | -$39.79 M(-29.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$14.82 M(-5.0%) | -$56.47 M(+12.5%) |
| Dec 2017 | -$50.18 M(+35.6%) | -$15.59 M(+29.2%) | -$50.18 M(+10.5%) |
| Sept 2017 | - | -$12.07 M(-13.8%) | -$45.41 M(+9.1%) |
| June 2017 | - | -$13.99 M(+64.2%) | -$41.62 M(+7.6%) |
| Mar 2017 | - | -$8.52 M(-21.2%) | -$38.69 M(+4.6%) |
| Dec 2016 | -$37.00 M(+69.3%) | -$10.82 M(+30.6%) | -$37.00 M(+14.6%) |
| Sept 2016 | - | -$8.28 M(-25.1%) | -$32.30 M(+11.6%) |
| June 2016 | - | -$11.06 M(+61.9%) | -$28.93 M(+27.7%) |
| Mar 2016 | - | -$6.83 M(+11.8%) | -$22.66 M(+3.6%) |
| Dec 2015 | -$21.86 M(-7.3%) | -$6.11 M(+24.3%) | -$21.86 M(-8.3%) |
| Sept 2015 | - | -$4.92 M(+2.6%) | -$23.85 M(-5.4%) |
| June 2015 | - | -$4.79 M(-20.6%) | -$25.21 M(-2.4%) |
| Mar 2015 | - | -$6.04 M(-25.4%) | -$25.84 M(+9.6%) |
| Dec 2014 | -$23.58 M(+171.3%) | -$8.10 M(+28.9%) | -$23.58 M(+24.2%) |
| Sept 2014 | - | -$6.28 M(+15.9%) | -$18.98 M(+18.1%) |
| June 2014 | - | -$5.42 M(+43.7%) | -$16.07 M(+40.3%) |
| Mar 2014 | - | -$3.77 M(+7.8%) | -$11.46 M(+31.8%) |
| Dec 2013 | -$8.69 M(+13.4%) | -$3.50 M(+3.9%) | -$8.69 M(+67.5%) |
| Sept 2013 | - | -$3.37 M(+316.3%) | -$5.19 M(+185.4%) |
| June 2013 | - | -$809.70 K(-19.7%) | -$1.82 M(+80.3%) |
| Mar 2013 | - | -$1.01 M | -$1.01 M |
| Dec 2012 | -$7.66 M | - | - |
FAQ
- What is Neoleukin Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual EBIT year-on-year change?
- What is Neoleukin Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly EBIT year-on-year change?
- What is Neoleukin Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics TTM EBIT year-on-year change?
What is Neoleukin Therapeutics annual earnings before interest & taxes?
The current annual EBIT of NLTX is -$59.10 M
What is the all time high annual EBIT for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual earnings before interest & taxes is -$7.53 M
What is Neoleukin Therapeutics annual EBIT year-on-year change?
Over the past year, NLTX annual earnings before interest & taxes has changed by +$1.60 M (+2.64%)
What is Neoleukin Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of NLTX is -$5.57 M
What is the all time high quarterly EBIT for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly earnings before interest & taxes is $2.69 M
What is Neoleukin Therapeutics quarterly EBIT year-on-year change?
Over the past year, NLTX quarterly earnings before interest & taxes has changed by +$8.04 M (+59.08%)
What is Neoleukin Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of NLTX is -$34.60 M
What is the all time high TTM EBIT for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high TTM earnings before interest & taxes is -$1.01 M
What is Neoleukin Therapeutics TTM EBIT year-on-year change?
Over the past year, NLTX TTM earnings before interest & taxes has changed by +$25.42 M (+42.35%)